$123.68 +2.36 (%) Pharmacyclics Inc - NASDAQ

Oct. 24, 2014 | 04:00 PM

Partner Headlines

  1. Pharmacyclics Enters Into Agreement With Roche To Evaluate IMBRUVICA And GAZYVA In Lymphoma And Leukemia

    Benzinga | Oct. 16, 2014 | 14:47PM EST
  2. Pharmacyclics and Servier Agree To Conclude Pan-HDAC Inhibitor Collaboration

    Benzinga | Sep. 25, 2014 | 16:02PM EST
  3. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  4. UPDATE: Morgan Stanley Reiterates On Pharmacyclics, Inc. Following VA Contract News

    Benzinga | Sep. 11, 2014 | 09:53AM EST
  5. Pharmacyclics Price Target Cut On Higher Spending

    IBD | Sep. 8, 2014 | 13:02PM EST
  6. Infinity Pharma Joins AbbVie On Blood Cancer Drug

    IBD | Sep. 3, 2014 | 13:20PM EST
  7. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD | Aug. 26, 2014 | 14:38PM EST
  8. Target Expected To Be Right On Target With Earnings

    Benzinga | Aug. 20, 2014 | 07:13AM EST
  9. Pharmacyclics Appoints Chief Commercial Officer

    Benzinga | Aug. 18, 2014 | 16:05PM EST
  10. Pharmacyclics Q2 Earnings Get Mixed Reception

    IBD | Aug. 1, 2014 | 12:35PM EST
  11. Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

    Benzinga | Jun. 30, 2014 | 09:18AM EST
  12. Pharmacyclics

    IBD | Jun. 9, 2014 | 18:41PM EST
  13. Surges In Biotech Short Interest (INCY, PCYC, RGEN)

    Benzinga | May. 11, 2014 | 16:35PM EST
  14. AbbVie Beats Q1 Estimates, Downplays HCV 'Price War'

    IBD | Apr. 25, 2014 | 12:30PM EST
  15. Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite Aid Moves Higher

    Benzinga | Apr. 10, 2014 | 15:34PM EST
  16. Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva Drops

    Benzinga | Apr. 10, 2014 | 12:48PM EST
  17. Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

    Benzinga | Apr. 8, 2014 | 08:01AM EST
  18. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga | Mar. 27, 2014 | 15:57PM EST
  19. Morgan Stanley Starts Pharmacyclics With Equal-Weight; $120 PT -Reuters

    Benzinga | Mar. 26, 2014 | 16:27PM EST
  20. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, PCYC)

    Benzinga | Mar. 26, 2014 | 07:56AM EST
  21. Pharmacyclics target raised

    IBD | Mar. 20, 2014 | 18:47PM EST
  22. Pharmacyclics Drug Imbruvica Beats Rivals: Nomura

    IBD | Mar. 20, 2014 | 11:25AM EST
  23. Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

    Benzinga | Mar. 19, 2014 | 13:31PM EST
  24. WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses

    IBD | Mar. 5, 2014 | 17:38PM EST
  25. Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

    GuruFocus | Mar. 3, 2014 | 09:31AM EST
  26. Pharmacyclics Hits High As Imbruvica Launches Big

    IBD | Feb. 21, 2014 | 12:31PM EST
  27. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga | Feb. 18, 2014 | 16:17PM EST
  28. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  29. Pharmacyclics up on FDA OK

    IBD | Feb. 12, 2014 | 18:43PM EST
  30. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD | Feb. 12, 2014 | 14:05PM EST
  31. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts | Jan. 22, 2014 | 09:25AM EST
  32. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts | Jan. 21, 2014 | 13:29PM EST
  33. ETF Outlook for Wednesday, January 8, 2014 (ROBO, PBE, SMH, EUFN)

    Benzinga | Jan. 8, 2014 | 07:31AM EST
  34. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD | Jan. 7, 2014 | 18:45PM EST
  35. Biotechs Jump On Drug News

    IBD | Jan. 7, 2014 | 18:40PM EST
  36. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD | Jan. 7, 2014 | 11:26AM EST
  37. The Top Five Drug Launches Of 2013

    IBD | Dec. 31, 2013 | 13:42PM EST
  38. Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)

    Benzinga | Dec. 26, 2013 | 13:26PM EST
  39. Qihoo, Noah Lead IBD 50's Top 5 Young Chinese Stocks

    IBD | Dec. 14, 2013 | 08:02AM EST
  40. Pharmacyclics Announces Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology

    Benzinga | Dec. 9, 2013 | 21:01PM EST
  41. Celgene, Infinity Rise On Blood Cancer Drug Data

    IBD | Dec. 9, 2013 | 11:24AM EST
  42. 2 Top Biotechs Presenting Data At Hematology Event

    IBD | Dec. 6, 2013 | 14:57PM EST
  43. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD | Dec. 5, 2013 | 18:21PM EST
  44. SouFun, Zeltiq Lead IBD's Top 5 With Bolting RS Lines

    IBD | Dec. 3, 2013 | 08:02AM EST
  45. UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech Sector Outlook Remains Strong

    Benzinga | Nov. 27, 2013 | 11:28AM EST
  46. Wedbush Reiterates on Pharmacyclics as IMBRUVICA Approved for Mantle Cell Lymphoma

    Benzinga | Nov. 14, 2013 | 10:54AM EST
  47. Market Wrap For November 13: Markets Await Janet Yellen's Big Day Thursday

    Benzinga | Nov. 13, 2013 | 16:49PM EST
  48. Pharmacyclics Drug Wins One Approval, Awaits Another

    IBD | Nov. 13, 2013 | 14:15PM EST
  49. The U.S. Food and Drug Adminstration Approves Pharmacyclis Product For Treatment of Disease

    Benzinga | Nov. 13, 2013 | 14:03PM EST
  50. Pharmacyclics, J&J's Janssen Now Confirming FDA Approval of IMBRUVICA

    Benzinga | Nov. 13, 2013 | 12:42PM EST
Trading Center